ARBUTUS BIOPHARMA CORP (ABUS)

Every figure this model derived for ABUS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 92,625,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 273,883,000 AssetsCurrent 2026-06-30
current liabilities 3,364,000 LiabilitiesCurrent 2026-06-30
equity 258,733,000 StockholdersEquity 2026-06-30
interest expense 76,000 InterestExpenseNonoperating 2026-06-30
ocf -24,625,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 181,720,000 Revenues 2026-06-30
sbc 5,509,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ABUS on one particular measure came for.

RatioValue
cash operating margin85.04
current ratio81.42
current ratio reported81.42
deferred revenue growth-100.0
dilution pct3.23
fcf margin-13.55
growth cv1.85
interest cover1960.46
operating margin81.99
owner earnings margin-16.58
revenue growth1078.78
revenue growth per share1041.89
roic70.86
rule of 401160.77
sbc pct revenue3.03

What to be careful about

What this model itself distrusts about ABUS's figures. Written by the derivation as it ran, not added afterwards.